Broschüre zu einem Colloquium

Publikationen

Publikationen aus dem Labor translationale Forschung, Stand Oktober 2024

  1. Engel, J., Wieder, V., Bauer, M., Kaufhold, S., Stückrath, K., Wilke, J., Hanf, V., Uleer, C., Lantzsch, T., Peschel, S., John, J., Pöhler, M., Weigert, E., Bürrig, K.-F., Buchmann, J., Santos, P., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2024. Prognostic and predictive impact of NOTCH1 in early breast cancer. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-024-07444-1
  2. Montero-Vergara J, Plachetta K, Kinch L, Bernhardt S, Kashyap K, Levine B, Thukral L, Vetter M, Thomssen C, Wiemann S, Peña-Llopis S, Jendrossek V, Vega-Rubin-de-Celis S., 2024. GRB2 is a BECN1 interacting protein that regulates autophagy. Cell death & disease 15 (1). https://doi.org/10.1038/s41419-023-06387-7
  3. Bauer, M., Vetter, M., Stückrath, K., Yohannes, M., Desalegn, Z., Yalew, T., Bekuretsion, Y., Kenea, T.W., Joffe, M., van den Berg, E.J., Nikulu, J.I., Bakarou, K., Manraj, S.S., Ogunbiyi, O.J., Ekanem, I.-O., Igbinoba, F., Diomande, M., Adebamowo, C., Dzamalala, C.P., Anele, A.A., Zietsman, A., Galukande, M., Foerster, M., dos-Santos-Silva, I., Liu, B., Santos, P., Jemal, A., Abebe, T., Wickenhauser, C., Seliger, B., McCormack, V., Kantelhardt, E.J., 2023. Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa. Cancer immunology research 11, 720–731. https://doi.org/10.1158/2326-6066.CIR-22-0795
  4. Desalegn, Z., Smith, A., Yohannes, M., Cao, X., Anberber, E., Bekuretsion, Y., Assefa, M., Bauer, M., Vetter, M., Kantelhardt, E.J., Abebe, T., Starlard-Davenport, A., 2023. Human Breast Tissue Microbiota Reveals Unique Microbial Signatures that Correlate with Prognostic Features in Adult Ethiopian Women with Breast Cancer. Cancers 15. https://doi.org/10.3390/cancers15194893
  5. Thomssen, C., Vetter, M., Kantelhardt, E.J., Meisner, C., Schmidt, M., Martin, P.M., Clatot, F., Augustin, D., Hanf, V., Paepke, D., Meinerz, W., Hoffmann, G., Wiest, W., Sweep, F.C.G.J., Schmitt, M., Jänicke, F., Loibl, S., Minckwitz, G. von, Harbeck, N., 2023. Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group. Cancers 15. https://doi.org/10.3390/cancers15051580
  6. Bachmann, H.S., Jung, D., Link, T., Arnold, A., Kantelhardt, E., Thomssen, C., Wimberger, P., Vetter, M., Kuhlmann, J.D., 2022. FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer. Cancers 14. https://doi.org/10.3390/cancers14030468
  7. Desalegn, Z., Yohannes, M., Porsch, M., Stückrath, K., Anberber, E., Santos, P., Bauer, M., Addissie, A., Bekuretsion, Y., Assefa, M., Worku, Y., Taylor, L., Abebe, T., Kantelhardt, E.J., Vetter, M., 2022. Intrinsic subtypes in Ethiopian breast cancer patient. Breast cancer research and treatment 196, 495–504. https://doi.org/10.1007/s10549-022-06769-z
  8. Erber, R., Angeloni, M., Stöhr, R., Lux, M.P., Ulbrich-Gebauer, D., Pelz, E., Bankfalvi, A., Schmid, K.W., Walter, R.F.H., Vetter, M., Thomssen, C., Mayr, D., Klauschen, F., Sinn, P., Sotlar, K., Stering, K., Stenzinger, A., Wunderle, M., Fasching, P.A., Beckmann, M.W., Hoffmann, O., Kimmig, R., Harbeck, N., Wuerstlein, R., Ferrazzi, F., Hartmann, A., 2022. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. International journal of molecular sciences 23. https://doi.org/10.3390/ijms23158716
  9. Reinhardt, K., Stückrath, K., Hartung, C., Kaufhold, S., Uleer, C., Hanf, V., Lantzsch, T., Peschel, S., John, J., Pöhler, M., Bauer, M., Bürrig, F.K., Weigert, E., Buchmann, J., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2022. PIK3CA-mutations in breast cancer. Breast cancer research and treatment 196, 483–493. https://doi.org/10.1007/s10549-022-06637-w
  10. Schüler, K., Bethmann, D., Kaufhold, S., Hartung, C., Stückrath, K., Lantzsch, T., Uleer, C., Hanf, V., Peschel, S., John, J., Pöhler, M., Buchmann, J., Bürrig, K.-F., Weigert, E., Thomssen, C., Kantelhardt, E.J., Vetter, M., 2022. Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients. Diagnostics (Basel, Switzerland) 12. https://doi.org/10.3390/diagnostics12102527
  11. Berdiel-Acer, M., Maia, A., Hristova, Z., Borgoni, S., Vetter, M., Burmester, S., Becki, C., Michels, B., Abnaof, K., Binenbaum, I., Bethmann, D., Chatziioannou, A., Hasmann, M., Thomssen, C., Espinet, E., Wiemann, S., 2021. Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. Oncogene 40, 2651–2666. https://doi.org/10.1038/s41388-021-01719-3
  12. Bley, N., Schott, A., Müller, S., Misiak, D., Lederer, M., Fuchs, T., Aßmann, C., Glaß, M., Ihling, C., Sinz, A., Pazaitis, N., Wickenhauser, C., Vetter, M., Ungurs, O., Strauss, H.-G., Thomssen, C., Hüttelmaier, S., 2021. IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. RNA biology 18, 391–403. https://doi.org/10.1080/15476286.2020.1812894
  13. Hartung, C., Porsch, M., Stückrath, K., Kaufhold, S., Staege, M.S., Hanf, V., Lantzsch, T., Uleer, C., Peschel, S., John, J., Pöhler, M., Weigert, E., Buchmann, J., Bürrig, K.-F., Schüler, K., Bethmann, D., Große, I., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2021. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. Breast care (Basel, Switzerland) 16, 637–647. https://doi.org/10.1159/000519255
  14. Mitra, D., Vega-Rubin-de-Celis, S., Royla, N., Bernhardt, S., Wilhelm, H., Tarade, N., Poschet, G., Buettner, M., Binenbaum, I., Borgoni, S., Vetter, M., Kantelhardt, E.J., Thomssen, C., Chatziioannou, A., Hell, R., Kempa, S., Müller-Decker, K., Wiemann, S., 2021. Abrogating GPT2 in triple-negative breast cancer inhibits tumor growth and promotes autophagy. International journal of cancer 148, 1993–2009. https://doi.org/10.1002/ijc.33456.
  15. Reibold, C.F., Tariku, W., Eber-Schulz, P., Getachew, S., Addisie, A., Unverzagt, S., Wienke, A., Hauptmann, S., Wickenhauser, C., Vetter, M., Jemal, A., Thomssen, C., Kantelhardt, E.J., 2021. Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. Breast care (Basel, Switzerland) 16, 484–490. https://doi.org/10.1159/000512840.
  16. Bauer, M., Kantelhardt, E.J., Stiewe, T., Nist, A., Mernberger, M., Politt, K., Hanf, V., Lantzsch, T., Uleer, C., Peschel, S., John, J., Buchmann, J., Weigert, E., Bürrig, K.-F., Wickenhauser, C., Thomssen, C., Bartel, F., Vetter, M., 2019. Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. Oncotarget 10, 1975–1992. https://doi.org/10.18632/oncotarget.26768
  17. Bley, N., Schott, A., Müller, S., Misiak, D., Lederer, M., Fuchs, T., Aßmann, C., Glaß, M., Ihling, C., Sinz, A., Pazaitis, N., Wickenhauser, C., Vetter, M., Ungurs, O., Strauss, H.-G., Thomssen, C., Hüttelmaier, S., 2021. IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. RNA biology 18, 391–403. https://doi.org/10.1080/15476286.2020.1812894
  18. Hartung, C., Porsch, M., Stückrath, K., Kaufhold, S., Staege, M.S., Hanf, V., Lantzsch, T., Uleer, C., Peschel, S., John, J., Pöhler, M., Weigert, E., Buchmann, J., Bürrig, K.-F., Schüler, K., Bethmann, D., Große, I., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2021. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. Breast care (Basel, Switzerland) 16, 637–647. https://doi.org/10.1159/000519255
  19. Mitra, D., Vega-Rubin-de-Celis, S., Royla, N., Bernhardt, S., Wilhelm, H., Tarade, N., Poschet, G., Buettner, M., Binenbaum, I., Borgoni, S., Vetter, M., Kantelhardt, E.J., Thomssen, C., Chatziioannou, A., Hell, R., Kempa, S., Müller-Decker, K., Wiemann, S., 2021. Abrogating GPT2 in triple-negative breast cancer inhibits tumor growth and promotes autophagy. International journal of cancer 148, 1993–2009. https://doi.org/10.1002/ijc.33456
  20. Reibold, C.F., Tariku, W., Eber-Schulz, P., Getachew, S., Addisie, A., Unverzagt, S., Wienke, A., Hauptmann, S., Wickenhauser, C., Vetter, M., Jemal, A., Thomssen, C., Kantelhardt, E.J., 2021. Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. Breast care (Basel, Switzerland) 16, 484–490. https://doi.org/10.1159/000512840
  21. Bauer, M., Kantelhardt, E.J., Stiewe, T., Nist, A., Mernberger, M., Politt, K., Hanf, V., Lantzsch, T., Uleer, C., Peschel, S., John, J., Buchmann, J., Weigert, E., Bürrig, K.-F., Wickenhauser, C., Thomssen, C., Bartel, F., Vetter, M., 2019. Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. Oncotarget 10, 1975–1992. https://doi.org/10.18632/oncotarget.26768
  22. Berchtold, E., Vetter, M., Gündert, M., Csaba, G., Fathke, C., Ulbrich, S.E., Thomssen, C., Zimmer, R., Kantelhardt, E.J., 2019. Comparison of six breast cancer classifiers using qPCR. Bioinformatics (Oxford, England) 35, 3412–3420. https://doi.org/10.1093/bioinformatics/btz103
  23. Kuhlmann, J.D., Bachmann, H.S., Link, T., Wimberger, P., Kröber, E., Thomssen, C., Mallé, B., Bethmann, D., Vetter, M., Kantelhardt, E.J., 2019. Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer. Scientific reports 9, 12594. https://doi.org/10.1038/s41598-019-47601-x

 

 

Buchbeitrag:

  1. Kantelhardt E.J., Vetter M., Strauß H-G.: Mammakarzinomrezidiv und metastasiertes Mammakarzinom. In: Wacker J, Sillem M, Bastert G, Beckmann MW (eds): Therapiehandbuch Gynäkologie und Geburtshilfe, 3. Auflage. Berlin, Heidelberg, Springer, 2020, pp 421–437.
  2. Kantelhardt, E.J., Vetter, M., Harbeck, N., Thomssen, C.: Praxisrelevante und evidenzbasierte prognostische und prädiktive Faktoren beim Mammakarzinom. In: Untch, M., Sittel, H. (eds): Diagnostik und Therapie des Mammakarzinoms, 5. Auflage. W. Zuckschwerdt, 2009, pp 229-239.

Herausgeberschaft:

  1. Tumorbiologie und Diagnostik des primären Mammakarzinoms, Hsgb. Vetter, M., Kantelhardt, E.J., UNI-MED SIENCE, Bremen, 2015, ISBN 978-3-8374-1492-9